Bleeding disorders disrupt the body’s ability to form a stable clot. Some are inherited and present in childhood, others are acquired and appear alongside another condition. What they share is that early recognition changes the outcome, and that recognition depends almost entirely on laboratory testing. The scale is significant: thromboembolic conditions accounted for around one in four deaths worldwide in 2010, making them a leading cause of mortality.
Inherited bleeding disorders affect large numbers of patients. In 2022, more than 257,000 people were confirmed to have hemophilia worldwide, with a further 100,000 living with von Willebrand disease.2 Both prevent the blood from clotting normally.
In-vitro diagnostics carries most of the diagnostic burden. Symptoms such as easy bruising, frequent nosebleeds or prolonged bleeding after a minor injury are common enough in the general population that they rarely prompt immediate investigation. It is the coagulation profile that separates ordinary from abnormal.
The Most Common Bleeding Disorders
Hemophilia
Hemophilia is an inherited disorder affecting predominantly males, caused by insufficient clotting factor: Factor VIII in hemophilia A, Factor IX in hemophilia B. It presents as prolonged bleeding from minor wounds, bleeding into joints and muscles, and a marked tendency to bruise. Untreated, repeated joint bleeds cause lasting damage, and major bleeding episodes can be life-threatening.
Diagnosis and monitoring rely on specific factor assays. Regular testing allows treatment, usually factor replacement therapy, to be adjusted to the individual patient and to prevent bleeding rather than respond to it. Hemophilia A accounts for the largest share of identified cases worldwide, followed by von Willebrand disease.
Von Willebrand disease
Von Willebrand disease results from a deficiency or dysfunction of von Willebrand factor, a protein central to platelet adhesion and clot formation. Presentation is typically milder than hemophilia and more variable, which is part of why it goes undiagnosed for longer. Common signs are nosebleeds, easy bruising and prolonged bleeding from mucous membranes, often noticed first during dental work, surgery or menstruation.
Diagnosis requires a panel rather than a single test, typically von Willebrand factor antigen assay alongside ristocetin cofactor activity, which together establish both the quantity and the function of the protein and allow the disorder to be subtyped.
Thrombocytopenia
Thrombocytopenia is a reduced platelet count, which may be inherited or acquired through medication, infection, autoimmune conditions or bone marrow disorders. Symptoms range from petechiae and easy bruising through to significant bleeding, depending on how far the count has fallen.
A complete blood count identifies the reduced count, and platelet function testing establishes whether the platelets that remain are working normally. Treatment depends on the cause: managing the underlying condition is sufficient in many cases, while others require medication or, in severe cases, platelet transfusion.
What Coagulation Analyzers Contribute
A coagulation analyzer measures how long plasma takes to clot under defined conditions, assesses the levels of individual clotting factors, and evaluates fibrinolytic activity. From these measurements the laboratory builds a profile that distinguishes one bleeding disorder from another.
Three things follow from automating this:
- Speed: Screening tests such as PT and APTT are returned quickly enough to guide decisions during an acute bleeding episode, not after it.
- Consistency: Clot detection by optical or mechanical means removes the variability inherent in manual timing methods.
- Monitoring: The same instruments track anticoagulant therapy, where the margin between under- and over-treatment is narrow and regular measurement is essential.
Early detection matters here more than in most areas of diagnostics. A patient identified before a major bleed can be managed prophylactically. A patient identified afterwards is managing consequences that were preventable.
Our offerings for early and accurate detection of coagulation disorders
Erba’s hemostasis range, backed by the research and manufacturing capability of parent group Transasia Bio-Medicals, covers semi-automated and fully automated coagulation testing. The ECL 105, ECL 412 and ECL 760 span requirements from small laboratories to high-throughput settings, supported by a reagent range including Erba D-Dimer R for quantitative D-dimer measurement.
The ECL systems include interactive displays, built-in printers, RFID, cuvette and reagent management, quality control software, and multi-standard curve calibration of up to six points. These features allow a broad range of coagulation tests to be performed reliably on a compact platform, which matters for laboratories that need full functionality without the footprint or throughput of a large reference system.
Awareness of bleeding disorders, and of the role diagnostics plays in identifying them, supports earlier intervention and better outcomes. Routine screening, timely diagnosis and treatment matched to the individual patient remain the foundation of effective management, and the quality of the laboratory result is what makes each of those possible.
References:
- Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016;118(9):1340-1347.
- https://www.statista.com/statistics/373108/worldwide-people-with-blood-disorders/
